Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach

The reason why triple-negative breast cancer is such a tough disease to treat is largely given away in its name. Such tumors can’t be defined by traditional biomarkers — neither estrogen receptors, progesterone receptors, nor excess HER2 protein — forcing drug hunters down uncharted new pathways.

Researchers at Vanderbilt-Ingram Cancer Center explored one of them, and turned up with some new suggestions.